Dynavax Technologies Corporation news

   Watch this stock
Showing stories 1 - 2 of about 2   

Articles published

DVAX 25.35 +0.21 (0.84%)
price chart
85% Probability Of FDA Approval For Dynavax's Heplisav, Says Cowen's Senior ...
Global stocks have sold off, as a result of disappointing earnings reports from large U.S. corporations. Investors looking to take advantage of recent weakness to search for value opportunities in the biotechnology industry have quite a few options ...
6 Stocks Trading Under $5 on Winning Streaks
Dynavax Technologies Corporation (DVAX, Earnings, Analysts, Financials): A clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases.